Nashville, TN, United States of America

Robert Carnahan

USPTO Granted Patents = 3 

 

Average Co-Inventor Count = 4.5

ph-index = 1

Forward Citations = 4(Granted Patents)


Location History:

  • Franklin, TN (US) (2015)
  • Nashville, TN (US) (2022)

Company Filing History:


Years Active: 2015-2025

Loading Chart...
Loading Chart...
3 patents (USPTO):Explore Patents

Title: The Innovations of Robert Carnahan

Introduction

Robert Carnahan is a prominent inventor based in Nashville, TN (US). He has made significant contributions to the field of biomedical research, particularly in the development of human monoclonal antibodies. With a total of three patents to his name, Carnahan's work has been pivotal in addressing critical health challenges.

Latest Patents

Among his latest patents, Carnahan has developed human monoclonal antibodies targeting the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). These antibodies are designed to bind to and neutralize the coronavirus, providing potential therapeutic methods for combating COVID-19. His innovative approach has garnered attention in the scientific community for its relevance and impact.

Career Highlights

Carnahan is affiliated with Vanderbilt University, where he conducts his research and development. His work has not only advanced scientific understanding but has also contributed to public health initiatives. His dedication to innovation in the field of immunology is evident through his patent portfolio.

Collaborations

Some of his notable collaborators include James E Crowe, Jr. and Seth Zost. Their combined expertise has further enhanced the research efforts in developing effective treatments against viral infections.

Conclusion

Robert Carnahan's contributions to the field of biomedical research, particularly through his patents on monoclonal antibodies, highlight his role as an influential inventor. His work continues to pave the way for advancements in therapeutic solutions for viral diseases.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…